Compare XGN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XGN | LEXX |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 7 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 14.5M |
| IPO Year | 2019 | N/A |
| Metric | XGN | LEXX |
|---|---|---|
| Price | $6.67 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.67 | $4.00 |
| AVG Volume (30 Days) | 246.3K | ★ 366.8K |
| Earning Date | 11-04-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,599,000.00 | $705,923.00 |
| Revenue This Year | $22.15 | $13.35 |
| Revenue Next Year | $15.26 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.08 | ★ 52.05 |
| 52 Week Low | $2.67 | $0.48 |
| 52 Week High | $12.23 | $2.43 |
| Indicator | XGN | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 34.53 |
| Support Level | $6.37 | $0.48 |
| Resistance Level | $7.29 | $1.44 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 35.48 | 19.53 |
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.